Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients.
Open Forum Infect Dis
; 8(7): ofab336, 2021 Jul.
Article
in English
| MEDLINE | ID: covidwho-1324647
ABSTRACT
BACKGROUND:
The coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes.METHODS:
We conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured.RESULTS:
Administration ofâ ≥8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70; Pâ <â .001) and 0.52 (95% CI, 0.31-0.87; Pâ =â .012) for all and intensive care unit-admitted patients, respectively. Decreased lengths of stay (9.2 vs 11.6; Pâ <â .001), frequencies of subsequent positive SARS-CoV-2 tests (53.6% vs 75.0%; Pâ =â .01), and long-term risks of ischemic cerebral ischemia (3.2% vs 6.1%; Pâ <â .001) were also noted.CONCLUSIONS:
If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
Open Forum Infect Dis
Year:
2021
Document Type:
Article
Affiliation country:
Ofid
Similar
MEDLINE
...
LILACS
LIS